Another recently published study has confirmed the efficacity of cannabis in the fight against pain. The study looked at cannabis use in oncology patients and found cannabis improved symptoms and reduced pain. It also confirmed that cannabis helps reduce dependence on addiction-inducing opioid pain management drugs. Surprisingly, it also found cannabis improved sexual function.
A new study from the Technion-Israel Institute of Technology (Haifa, Israel) reaffirms the effectiveness of medical cannabis in relieving pain. In addition, it also confirms that cannabis can reduce the need for opioid analgesics in cancer patients.
Given minimal side effects, medical cannabis can be considered an alternative to painkillers usually prescribed to cancer patients, underlines this study, published in the journal Frontiers in Pain Research.
To keep abreast of the latest cannabis research updates, download our free hemp and cannabis news app.
This comprehensive review of the benefits of medical cannabis for cancer-related pain confirms, for most oncology patients, significant improvement in pain measures but also other cancer-related symptoms, including depression, anxiety, depression, and insomnia.
By relieving these symptoms, which are among the most significant factors of suffering and degradation of the quality of life in oncology patients, cannabis also makes it possible to prevent the worsening of the condition and the prognosis.
“Traditionally, cancer pain has been treated with opioid analgesics, but most oncologists perceive opioid treatment as dangerous, so there is a real need for treatment alternatives,” says lead author David Meiri, Professor at the Technion Israel Institute of Technology. It was by speaking with cancer patients who were looking for alternatives to relieve pain and symptoms that the team sought to assess the benefits of medical cannabis thoroughly.
The researchers first analyzed data from the existing literature but considered that ultimately, “not much was known about the effectiveness of medical cannabis for the treatment of cancer-related pain, and that most of the available results were inconclusive.”
Therefore, the researchers collected information from the start of the treatment and then during repeated follow-ups over an extended period so that they could carry out a thorough analysis of its effectiveness.
Oncologists capable of dispensing medical cannabis prescriptions to their cancer patients were recruited. These oncologists referred patients to the study and reported on the characteristics of their disease. The patients were informed about their symptoms by anonymous questionnaires before starting the treatment, then several times during the following six months.
The analysis included measures of pain, painkiller consumption, cancer symptoms, sexual problems, and side effects. The analysis reveals:
Almost half of the participants eventually stopped all painkillers after 6 months of treatment with medical cannabis.
“Interestingly, we find that sexual function improves with medical cannabis for most men but deteriorates for most women,” note the researchers who plan to conduct further research on the effects of medical cannabis according to patient groups.
—
(Featured image by Thirdman via Pexels)
DISCLAIMER: This article was written by a third-party contributor and does not reflect the opinion of Hemp.im, its management, staff, or its associates. Please review our disclaimer for more information.
This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.
First published by Sante Log, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.
Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Hemp.im assumes no responsibility for errors, omissions, or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Hemp.im is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.
The DEA has postponed a key hearing on the reclassification of cannabis. The hearing was…
A new California Department of Public Health report has come out with recommendations for THC…
Ontario is investing $31 million over the next three years to enhance efforts against illegal…
Frankfurt and Hanover are launching five-year pilot projects for legal, regulated cannabis sales to adults,…
Italy's Regional Administrative Court suspended the Health Ministry's decree labeling CBD as a narcotic, pending…
This November, five U.S. states will vote on measures related to legalizing recreational or medical…